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Key Points 
• Csk and CD148 are non-redundant regulators of SFKs in platelets and deletion of 
either induces cell-intrinsic negative feedback mechanisms 
• Csk is a negative regulator of SFK activity, whereas CD148 is a dual positive and 
negative regulator of SFK activity in platelets 
 
Abstract 
Src family kinases (SFKs) coordinate the initiating and propagating activation signals in 
platelets, however it remains unclear how they are regulated.  Here we show that ablation of 
C-terminal Src kinase (Csk) and receptor-like protein tyrosine-phosphatase CD148 in mice 
results in a dramatic increase in platelet SFK activity, demonstrating that these proteins are 
essential regulators of platelet reactivity.  Paradoxically, Csk/CD148-deficient mice exhibit 
reduced in vivo and ex vivo thrombus formation and increased bleeding following injury, 
rather than a prothrombotic phenotype.  This is a consequence of multiple negative feedback 
mechanisms, including downregulation of the immunoreceptor tyrosine-based activation 
motif (ITAM)- and hemi-ITAM-containing receptors GPVI-FcR γ-chain and CLEC-2, 
respectively and upregulation of the immunoreceptor tyrosine-based inhibition motif (ITIM)-
containing receptor G6b-B and its interaction with the tyrosine phosphatases Shp1 and Shp2.  
Results from an analogue-sensitive Csk mouse model demonstrate the unconventional role of 
SFKs in activating ITIM signaling.  This study establishes Csk and CD148 as critical 
molecular switches controlling the thrombotic and hemostatic capacity of platelets, and 
reveals cell-intrinsic mechanisms that prevent pathological thrombosis from occurring. 
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Introduction 
Platelets are highly reactive fragments of megakaryocytes (MKs) that interrogate the vessel 
wall and prevent excessive blood loss following injury.  They do so by adhering to exposed 
extracellular matrix proteins and forming a thrombus that transiently occludes the blood 
vessel, promoting wound repair and vessel regeneration.  However, it remains unclear how 
the reactivity of platelets in the circulation is regulated.  
Platelets contain high levels of Src family kinases (SFKs) that have a coordinating 
role in initiating and propagating primary activation signals.1,2  The three most abundant 
SFKs in human and mouse platelets are Src, Lyn and Fyn (Figure S1).3,4  Src and Fyn act 
primarily as positive regulators of platelet activation,5-8 whereas Lyn is both a positive and 
negative regulator of activation.9,10  SFKs are constitutively associated with the cytoplasmic 
tails of several important platelet receptors, including: the glycoprotein (GP)Ib-IX-V 
complex,11,12 the immunoreceptor tyrosine-based activation motif (ITAM)-containing GPVI-
FcR γ-chain receptor complex,5,13 and the integrin αIIbβ3.14,15  SFKs are also involved in 
transmitting secondary activation signals from G protein-coupled receptors.16-21 
Equally important, but less well understood are the inhibitory functions of SFKs.  
Concomitant with phosphorylating ITAM-containing receptors activating platelets,5,22 SFKs 
also phosphorylate immunoreceptor tyrosine-based inhibition motif (ITIM)-containing 
receptors that inhibit platelets.23  The latter recruit SH2 domain-containing phosphatases, 
including the non-transmembrane protein-tyrosine phosphatases Shp1 and Shp2,24-26 that 
inhibit platelet activation.  The two most well characterized platelet ITIM-containing 
receptors are PECAM-1 and G6b-B, which inhibit platelet activation and modulate platelet 
homeostasis, respectively.27,28 
Limited knowledge has been gained how platelet SFKs are regulated. SFKs are 
primed by dephosphorylation of the C-terminal inhibitory phospho-tyrosine residue by the 
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receptor-like tyrosine phosphatase CD45 in most hematopoietic cells,29 and by CD148 in 
platelets.30-32  Primed SFKs need to be fully activated through trans-auto-phosphorylation of 
a tyrosine residue located within the catalytic domain.33  On the other hand, inactivation of 
SFKs can occur through the action of C-terminal Src kinase (Csk) and the structurally-related 
Csk homologous kinase (Chk), also referred to as megakaryocyte-associated tyrosine kinase 
(Matk), both of which target the C-terminal inhibitory tyrosine residue in SFKs.34,35  
However, it remains unknown how the threshold of individual SFK activation is set in 
platelets  
To address these questions, we generated a series of MK-specific conditional 
knockout (KO) mouse models leading to deletion of Csk, CD148 or Csk/CD148, and studied 
the consequences of these deletions for platelet physiology.  Disruption of the homeostatic 
balance of SFK activity in MKs had dramatic and unexpected consequences on the number 
and reactivity of platelets in the circulation, due to cell-intrinsic negative feedback 
mechanisms, involving the ITIM-containing receptor G6b-B and Chk, culminating in anti-
thrombotic and hemorrhagic outcomes.   
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Materials and methods 
Mice 
Cskfl/fl, CD148fl/fl, Pf4-Cre+ and CskAS mice were generated, as previously described.36-39  All 
mice were on a C57BL/6 background.  All procedures were undertaken with United Kingdom 
Home Office approval in accordance with the Animals (Scientific Procedures) Act of 1986. 
 
Antibodies and reagents 
Thiazole orange (BD Retic-CountTM) were from BD Bioscience.  PP1 analogue IV (3-IB-
PP1) was from Calbiochem.  Antibodies are described in detail in Supplemental Methods. 
 
Immune thrombocytopenia  
Thrombocytopenia was induced as previously described.28  
 
Platelet preparation 
Blood was collected from terminally CO2-narcosed mice from the abdominal vena cava into 
1:10 (v:v) acid-citrate-dextrose anticoagulant.  Washed platelets were prepared as previously 
described.40  Adenosine diphosphate (ADP)-sensitive washed platelets were prepared in the 
presence of  ADP scavenger apyrase as previously described.41  Platelet counts were 
normalized and used for spreading (2 × 107/ml), aggregation (2 × 108/ml) or biochemical 
analysis (4 - 5 × 108/ml). 
 
Platelet functional assays and biochemistry 
Platelet aggregation, adenosine triphosphate (ATP) secretion, spreading, clot retraction, 
platelet adhesion under flow, total thrombus-formation analysis system (T-TAS), stimulation 
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for biochemical analysis, immunoblotting and immunoprecipitation are described in detail in 
Supplemental Methods. 
 
Flow cytometry 
Reticulated platelets in blood were double stained with αIIb and thiazole orange (BD Retic-
CountTM, BD Bioscience).  Surface protein expression was measured in blood or bone 
marrow cells with indicated FITC- or PE-conjugated antibodies by flow cytometry (BD 
Accuri C6 for platelets; BD FACSCalibur for bone marrow cells), as previously 
described.25,28  
 
Tail bleeding assay 
Experiments were performed on 8-10 week old KO and litter-matched WT mice as previously 
described.30  
 
In vivo thrombosis assays 
Laser-induced injury of arterioles in the cremaster muscle and ferric chloride-induced injury 
of carotid arteries were performed and analyzed as previously described.42 
 
Statistical analysis 
Data presented are means ± standard errors of the mean (SEM).  One-way or two-way 
ANOVA followed by post-hoc tests were used to determine statistical significance (P < .05).  
Further details on statistical analysis are provided in Supplemental Methods.  
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Results 
Rescue of thrombocytopenia in Csk/CD148-deficient mice 
MK-specific Csk and CD148 conditional KO (Csk and CD148 KO) mice were generated by 
crossing Cskfl/fl and CD148fl/fl mice with Pf4-Cre+ transgenic mice, respectively.36-38  
Csk/CD148 conditional double KO (DKO) mice were also generated, to determine if deletion 
of both enzymes simultaneously would rescue phenotypes of single KO mice, and to reveal 
novel mechanisms of SFK regulation (Figure 1A). 
Platelet count in Csk KO mice was reduced by 65% and platelet volume increased by 
33% (Figure 1B and Table S1), suggesting defects in platelet production and/or clearance.  
This was supported by a 2-fold increase in the proportion of reticulated, immature platelets in 
these mice (Figures 1C and S2A).  The same parameters were normal in CD148 KO mice 
(Figures 1B-C and S2A).  While the platelet count was normal in DKO mice, the variability 
in numbers was greater than in wild-type (WT) and Csk KO mice, and the proportion of large, 
reticulated platelets was similar to that in Csk KO mice (Figures 1B-C, S2A and Table S1).  
Increased numbers of immune and granulocytic cells in Csk and DKO mice (Table S1) may 
be an indirect consequence of non-specific deletion of floxed Csk and CD148 in other 
hematopoietic lineages by the Pf4-Cre transgene, which is reported to be ‘leaky’.43  
Interestingly, the proportion of P-selectin+αIIb+ platelets were normal in Csk KO mice and 
only marginally elevated in DKO mice (Figure S2B), pointing to only minimal pre-activation 
of these platelets in the circulation or downregulation of activation markers. 
To explore whether increased platelet size and proportion of young platelets correlate 
with changes in other platelet parameters, we quantified levels of receptors that regulate 
platelet production and activation.  Notably several receptors we focused on, including 
αIIbβ3, GPIbα, GPVI-FcR γ-chain, CLEC-2 and G6b-B rely on SFKs to transmit signals.2  
Surface levels of integrin αIIb were marginally increased in DKO platelets, whereas GPIbα 
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levels were increased by 63% and 38% in Csk KO and DKO platelets, respectively (Figure 
1Di).  Surface levels of GPVI were reduced by 77%, 44% and 88% in Csk KO, CD148 KO 
and DKO platelets, respectively, correlating with total protein levels of GPVI and FcR γ-
chain (Figure 1Di-ii).  Surface and total protein levels of CLEC-2 were reduced in Csk KO 
and DKO platelets, which were significantly more pronounced in DKO (Figure 1Di-ii).  In 
contrast, surface expression of the inhibitory receptor G6b-B was increased by 61% and 73% 
in Csk KO and DKO platelets, respectively, correlating with total protein levels (Figure 1Di-
ii).  Surface levels of the integrin α2 subunit and metalloproteinase ADAM10 that mediates 
shedding of GPVI were normal (Figure S3A).  Intriguingly, expression of surface receptors in 
αIIb+ bone marrow cells was normal in all three genotypes (Figure S3B), suggesting auto-
regulation of these receptors in platelets.  Collectively, these findings demonstrate 
downregulation of the (hemi-)ITAM-containing activation receptors GPVI-FcR γ-chain and 
CLEC-2, and concomitant upregulation of the ITIM-containing inhibitory receptor G6b-B in 
Csk-deficient platelets. 
To investigate the cause of low platelet counts, we measured the rate of platelet 
recovery following anti-GPIbα antibody-mediated platelet depletion.  This was significantly 
reduced in Csk KO mice, marginally reduced in CD148 KO and normal in DKO mice (Figure 
1Ei-ii).  The clearance of biotinylated platelets was normal in mice of all three genotypes 
(Figure S4A-B).  Both Csk KO and DKO mice exhibited splenomegaly (Figure S5A-B).  
Elevated MK counts were observed in spleens in all three genotypes, which was associated 
with myelofibrosis (Figure S6A).  MK counts were moderately elevated in the bone marrow 
of Csk KO mice, but with no associated myelofibrosis (Figure S6B).  We observed more P-
selectin+αIIb+ hematopoietic cells in Csk KO and DKO mice (Figure S6C), which may 
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explain the presence of myelofibrosis in the spleen of these mice.44  Together, these findings 
suggest defective MK activation in Csk KO and DKO mice. 
 
Hemostatic and thrombotic defects in Csk/CD148-deficient platelets 
We hypothesized that Csk KO mice would be predisposed to thrombosis, due to increased 
SFK activity, rendering platelets hyperactive.  To test this, we analyzed mice of all three 
genotypes in established in vivo models of hemostasis and thrombosis.  Paradoxically, Csk 
KO mice exhibited increased bleeding in a tail injury model (Figure 2A).  CD148 KO mice 
exhibited normal hemostasis, whereas DKO mice had increased bleeding compared to Csk 
KO mice (Figure 2A).  Increased bleeding in Csk KO and DKO mice could not be explained 
solely by reduced platelet count, which was normal in DKO mice. 
To explore the kinetics of arterial thrombus formation, we employed the laser injury-
induced thrombosis model in small arterioles in mice.  Thrombus formation and fibrin 
deposition were moderately and severely reduced in Csk KO and DKO mice, respectively 
(Figure 2Bi-iv and Videos 1-2).  Thrombus formation was also severely compromised in 
CD148 KO mice, whereas fibrin deposition was only moderately reduced (Figure 2Bi-iv).  
Similar results were observed following FeCl3-induced injury of the carotid artery, albeit 
thrombus formation was marginally better in CD148 KO compared with Csk KO mice 
(Figure 2Ci-iii and Video 3).  These results demonstrate that the ability of Csk KO and DKO 
mice to form thrombi in vivo is markedly reduced, resulting in increased bleeding. 
 
Aberrant platelet function underlies thrombotic and defects  
To determine the cause of reduced thrombus formation observed in the different in vivo 
models, we employed the T-TAS microfluidic device, which can differentiate between 
platelet- and coagulation-driven defects.  We found that platelets of all three genotypes 
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displayed severe defects in forming stable platelet thrombi on collagen surface, as we were 
unable to detect an increase in the flow pressure (Figure 3Ai).  However, under conditions 
where platelets were flowed over collagen in the presence of tissue factor to maximize 
coagulation, platelets of all three genotypes formed equally stable thrombi (Figure 3Aii), 
suggesting coagulation is unaltered in these mice and that defects in thrombus formation are 
intrinsic to platelets. 
To identify specific platelet defects, we measured multiple parameters of platelet 
function and thrombus formation ex vivo at arterial shear rates on collagen I, von Willebrand 
factor-binding peptide (vWF-BP) and laminin, and vWF-BP, laminin and the snake venom 
rhodocytin, which induces CLEC-2 signaling.  We found markedly decreased platelet 
deposition and thrombus formation on collagen I in Csk KO and CD148 KO samples, which 
were further reduced in DKO samples (Figure 3Bi-iii and vi).  α-granule secretion, integrin 
αIIbβ3 activation and phosphatidylserine (PS) exposure (determined as P-selectin, JON/A 
and Annexin V staining, respectively) followed the same trends (Figure 3Biv-vi).  This likely 
is a consequence of markedly reduced surface levels of GPVI-FcR γ-chain, defective SFK 
signaling and increased inhibitory mechanisms.  We found no difference between genotypes 
in platelet deposition on the vWF-BP and laminin surface on which adhesion is mediated by 
platelet GPIbα via immobilized plasma vWF and platelet integrin α6β1, which binds 
laminin,45 suggesting Csk and CD148 do not play major roles regulating GPIbα or α6β1 
signaling pathways (Figure 3Bi-ii and vi).  Upon complementing the vWF-BP and laminin 
surface with the CLEC-2 ligand rhodocytin, which drives a more robust platelet deposition,46 
adhesion was significantly reduced in the three KOs (Figure 3Bi-ii, vi).  Notably, CLEC-2 
expression was marginally and markedly reduced in Csk KO and DKO platelets, respectively, 
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demonstrating that Csk and CD148 participate in SFK regulation during CLEC-2-evoked 
hemi-ITAM signaling, as previously described.32 
 We next analyzed platelets of all three genotypes in a range of in vitro functional 
assays.  Consistent with previous findings, CD148 KO platelets exhibited reduced 
aggregation and ATP secretion to collagen and CRP stimulation, which was overcome at high 
concentrations of CRP (Figure 3Ci-ii).  Csk KO and DKO platelets also exhibited reduced 
reactivity to collagen, and failed to respond to collagen-related peptide (CRP) (Figure 3Ci-ii).  
We also investigated the aggregation and ATP secretion response of platelets to anti-CLEC-2 
antibody-mediated activation.  CD148 KO platelets exhibited an increase in the lag time at 
low concentration of anti-CLEC-2 antibody, and responded normally to a high concentration 
(Figure 3Ciii).  In contrast, Csk KO and DKO platelets exhibited shortened lag times in 
response to anti-CLEC-2 antibody, despite expressing lower levels of CLEC-2 receptor 
(Figures 1Di-ii and 3Ciii).  Platelets from all three mouse models responded normally to 
thrombin and TxA2 analogue U46619 (Figure 3Civ-v).  As expected, WT platelets prepared in 
the absence of apyrase did not respond to 10 μM ADP, due to P2Y1 and P2Y12 receptor 
desensitization (Figure 3Cvi); however, Csk KO and DKO platelets were able to aggregate 
and secrete ATP in response to the same concentration of ADP (Figure 4Cvi), suggesting 
reduced P2Y1 and P2Y12 internalization or increased signaling via these receptors, both of 
which utilize SFKs to transmit signals.2  Indeed, washed platelets prepared in the presence of 
apyrase, preventing receptor desensitization, responded normally to 3 and 10 μM ADP, 
except for DKO platelets, which hyper-responded (Figures 3Cvii and S7), supporting the 
hypothesis of increased P2Y12 signaling.  
We investigated platelet adhesion and spreading on fibrinogen, which is dependent on 
SFK-mediated αIIbβ3 outside-in signaling and cytoskeletal remodeling.  As expected, Csk-
deficient platelets spread to a greater extent than WT platelets, whereas CD148-deficient 
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platelets exhibited reduced spreading (Figure 3Di-ii).  However, DKO platelets spread 
comparably to WT platelets, suggesting that negative feedback mechanisms were activated in 
DKO platelets.  When platelets were pre-activated with thrombin, spreading of Csk KO and 
DKO platelets were significantly increased compared to WT (Figure 3Di-ii). 
To further test the role of Csk and CD148 in αIIbβ3 signaling, we assessed clot 
retraction in these mice in vitro, revealing a significant reduction in clot retraction of CD148 
KO platelets (Figure 3E).  These results strongly suggest an important role for functional Src 
kinase activity in clot retraction. 
 
Increased SFK activity in Csk/CD148-deficient platelets 
To determine the mechanism underlying the hypo-thrombotic phenotypes, we assessed SFK 
activity in unstimulated platelets of all three genotypes.  We measured trans-auto-
phosphorylation of the activation loop tyrosine residue of SFKs (Src p-Tyr418) as an indirect 
indicator of SFK activity in resting platelets by quantitative capillary electrophoresis-based 
immunoassays (ProteinSimple Wes).  As expected, deletion of Csk resulted in a significant 
increase in Src p-Tyr418, whereas deletion of CD148 resulted in a marked decrease in Src p-
Tyr418 (Figure 4Ai-ii).  Deletion of both Csk and CD148 resulted in an unexpected overall 
increase in Src p-Tyr418, demonstrating high activity SFKs in these platelets (Figure 4Ai-ii 
and B). 
Phosphorylation of the C-terminal inhibitory tyrosine residues of Lyn (Tyr507), Src 
(Tyr529) and Fyn (Tyr530) is typically inversely related to SFK activity and to Src p-Tyr418. 
Indeed, phosphorylated Lyn Tyr507 (Lyn p-Tyr507) was not detected in resting Csk-deficient 
platelets (Figure 4Ai-ii), and phosphorylation of Src Tyr529 (Src p-Tyr529) and Fyn Tyr530 
(Fyn p-Tyr530) were markedly decreased, suggesting that Csk is the main kinase that 
phosphorylates these residues and attenuates the activity of these SFKs.  Conversely, 
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phosphorylation of all three inhibitory tyrosine residues was increased in resting CD148-
deficient platelets (Figure 4Ai-ii), confirming previous findings that CD148-induced 
dephosphorylation activates SFKs in platelets.31  A partial rescue of Lyn p-Tyr507, Src p-
Tyr529 and Fyn p-Tyr530 was observed in DKO platelets (Figure 4Ai-ii), suggesting that in 
the absence of Csk and CD148 another kinase phosphorylates these residues, the obvious 
candidate being Chk, which was upregulated in Csk KO and DKO platelets (Figure 4C), 
explaining the rescue of inhibitory site phosphorylation of SFKs in DKO platelets.  
Expression of the tyrosine phosphatases PTP-1B, Shp1 and Shp2, all of which have been 
implicated in regulating SFK activity were normal in all three genotypes (Figure 4C).  
Interestingly, SFK activity (Src p-Tyr418) was highest in DKO platelets, despite increased 
phosphorylation of the C-terminal inhibitory tyrosine residues of Lyn, Src and Fyn, compared 
with Csk KO platelets.  It remains to be determined whether phosphorylation of the activation 
loop and C-terminal inhibitory tyrosine residues co-exist in the same molecules or in distinct 
pools of SFKs.  Dually phosphorylated SFKs have been reported to be active in T cells.47 
We next assessed whether SFK activity in MKs is comparable to platelets.  Indeed, 
SFKs were similarly phosphorylated in starved BM-derived MKs (Figure S8A-B) as they 
were in resting platelets of the same genotype (Figure 4Ai-ii), compatible with increased SFK 
activity in Csk KO and DKO MKs, and decreased SFK activity in CD148 KO MKs, which 
may underlie aberrant MK function and myelofibrosis in Csk KO and DKO mice.   
Collectively, these findings demonstrate that Csk is an inhibitor of SFK activity in 
platelets and MKs.  The finding that DKO platelets display markedly elevated SFK activity 
compared to Csk KO platelets suggest that CD148 can act as a dual activator and inhibitor of 
SFK activity in platelets and MKs (Figure 4B). 
 
ITAM and integrin receptor signaling is differentially regulated by Csk and CD148 
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To determine why platelets with high SFK activity were hypo-reactive, we investigated 
tyrosine phosphorylation downstream of GPVI-FcR γ-chain, CLEC-2 and αIIbβ3, all of 
which rely on SFKs and Syk to initiate and propagate signaling.  Due to the dramatic 
reduction of GPVI-FcR γ-chain expression in Csk KO and DKO platelets (Figure 1Di-ii), 
platelets were stimulated with a high concentration of collagen (30 μg/ml), which signals 
primarily through GPVI-FcR γ-chain.  Basal whole cell tyrosine phosphorylation (p-Tyr) and 
Src p-Tyr418 were significantly increased in resting DKO platelets and collagen-stimulated 
Csk KO and DKO platelets compared with WT platelets (Figure 5Ai-iii and S9A).  In contrast, 
basal and collagen-mediated Src p-Tyr418 was significantly reduced in CD148 KO platelets 
compared with WT platelets (Figure 5Ai-iii and S9A).  Induced phosphorylation of the FcR γ-
chain, which is directly mediated by SFKs and acts as a docking site for Syk, was less 
pronounced in Csk KO and DKO platelets (Figure 5Ai) due to reduced expression of the FcR 
γ-chain in these platelets (Figure 1Dii).  Syk activation was indirectly measured as 
phosphorylation of Syk tyrosine residues 525 and 526 (Syk p-Tyr525/6), and correlated 
directly with FcR γ-chain levels and phosphorylation.  Syk p-Tyr525/6 was highest in 
collagen-stimulated WT platelets, and increased only marginally in collagen-stimulated 
platelets of all three genotypes (Figure 5Aii-iii and S9A), despite Csk KO and DKO platelets 
having high SFK activity.  These findings support a model in which receptor-mediated 
membrane localization of Syk is essential for activation. 
Platelets were also stimulated with a high concentration of anti-CLEC-2 antibody (10 
μg/ml), mimicking podoplanin-mediated cross-linking of the receptor.  The pattern and 
intensity of whole cell p-Tyr and SFK phosphorylation generally mirrored that of collagen-
stimulation in the various genotypes (Figure 5Bi-iii and S9B).  However, Syk p-Tyr525/6 
was much higher in Csk KO platelets compared with any of the other genotypes (Figure 5Bii-
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iii and S9B), despite reduced CLEC-2 expression.  Despite the reduced CLEC-2 and GPVI-
FcR γ-chain levels in DKO platelets, stimulation by anti-CLEC-2 antibody resulted in normal 
Syk p-Tyr525/6, whereas stimulation by collagen led to significantly reduced Syk 
phosphorylation, correlating with normal and reduced aggregation, respectively. 
We also investigated αIIbβ3 signaling to determine the cause of increased spreading 
of Csk KO platelets on fibrinogen (Figure 3Di-ii).  To initiate signaling, αIIbβ3 relies mainly 
on Src, and to a lesser extent Fyn and is localized exclusively in non-lipid rafts.8,15,48,49  
Whole cell p-Tyr was increased in fibrinogen-adhered Csk KO and DKO platelets (Figure 
5Ci), demonstrating a general increase in outside-in integrin signaling in these platelets.  In 
agreement with increased spreading of Csk KO platelets, but normal spreading of DKO 
platelets on fibrinogen (Figure 3Di-ii, basal), we found increased SFK and Syk activities in 
Csk KO platelets, but not significantly higher SFK and Syk activities in DKO platelets 
(Figure 5Cii-iv and S9C). 
In addition to the elevated expression of the ITIM-containing receptor G6b-B in Csk 
KO and DKO platelets (Figure 1Di-ii), we found a marked increase in G6b-B tyrosine 
phosphorylation and binding of the tyrosine phosphatases Shp1 and Shp2 under resting and 
collagen-stimulated conditions (Figure 5Di), suggesting increased inhibitory signaling via the 
G6b-B-Shp1-Shp2 complex in Csk KO and DKO platelets (Figure 5Dii).  Thus, increased 
SFK activity in Csk KO and DKO platelets leads to compensatory upregulation of inhibitory 
ITIM signaling and parallel downregulation of the (hemi-)ITAM-containing GPVI-FcR γ-
chain and CLEC-2 receptors, explaining the reduced activity of these platelets. 
 
Csk is a critical inhibitor of ITAM- and integrin-mediated platelet activation  
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To circumvent developmental and compensatory mechanisms arising from deletion of Csk, 
we utilized a transgenic mouse model expressing a PP1-analogue (3-IB-PP1) sensitive form 
of Csk (CskAS), enabling rapid and specific inhibition of CskAS in these mice.39  Platelet count, 
volume and receptor expression were normal in CskAS mice (data not shown).  Platelets from 
CskAS mice aggregated and secreted normally to all agonists tested in the presence of vehicle 
alone (dimethyl sulfoxide, DMSO) (Figure 6Ai-iv), and marginally more robustly to a sub-
threshold concentration of anti-CLEC-2 antibody (3 μg/ml) in the presence of 10 μM 3-IB-
PP1 (Figure 6Aiii).  Inhibitor-treated CskAS platelets also spread marginally better than 
control on fibrinogen (Figure 6Bi-ii).  Collectively, these findings validate that Csk is an 
inhibitor of both ITAM and integrin receptor mediated platelet functions.  SFK activity (Src 
p-Tyr418) was significantly increased in resting, CRP (30 μg/ml) and anti-CLEC-2 antibody 
(10 μg/ml) stimulated CskAS platelets treated with 10 μM 3-IB-PP1 (Figures 6Ci-iii, Di-iii 
and S10A-B).  However, Lyn p-Tyr507, Src p-Tyr529 and Fyn p-Tyr530 were only 
minimally reduced in the presence of 3-IB-PP1 (Figure 6Cii-iii, Dii-iii and S10A-B), 
suggesting that tyrosine phosphatases do not automatically dephosphorylate these residues in 
the absence of Csk.  Syk activity was significantly increased at later time points post CRP-
stimulation (Figure 6Cii-iii and S10A).  Concomitantly, G6b-B was hyper-phosphorylated 
and had more associated Shp1 and Shp2 in collagen-stimulated CskAS platelets treated with 3-
IB-PP1 (Figure 6E).  As G6b-B KO platelets display markedly elevated Syk activity,28 we 
hypothesized that the increased inhibitory signaling provided by G6b-B impeded further 
enhancement of CRP- and CLEC-2 antibody-mediated aggregation and overall tyrosine 
phosphorylation in CskAS platelets.  These findings suggest that SFKs activate inhibitory 
pathways in parallel with activation pathways, to prevent platelet hyper-activation. 
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Discussion 
Here we describe a fundamental mechanism controlling SFK activity in the MK lineage, 
involving the kinase Csk, and the phosphatase CD148.  We show that Csk is a major inhibitor 
of SFKs in platelets, whereas CD148 primarily activates SFKs, but also attenuates SFK 
activity under as yet undefined conditions (Figures 4B and 7A).  These functions of Csk and 
CD148 correlate with what has previously been described in immune cells.31,50-55  We show 
that lack of Csk in the MK lineage in mice results in increased SFK activity in platelets, 
paradoxical bleeding and reduced thrombosis due to negative feedback mechanisms, 
including downregulation of (hemi-)ITAM-containing receptors, and concomitant 
upregulation of the inhibitory ITIM-containing receptor G6b-B rendering platelets less 
responsive to vascular injury (Figure 7B).  In contrast, deletion of CD148 results in reduced 
SFK activity and thrombus formation as a consequence of reduced (hemi-)ITAM and integrin 
receptor signaling.  Bleeding was however normal in CD148 KO mice due to residual SFK 
activity and intact positive feedback mechanisms.  Intriguingly, deletion of both Csk and 
CD148 markedly increased SFK activity, with more pronounced bleeding and thrombotic 
defects than in Csk KO mice, due to enhanced negative feedback effects (Figure 7B).  A 
summary of the phenotypes of Csk KO, CD148 KO and DKO mice is provided in Table 1.  
Thus, sustained high SFK activity in platelets does not culminate in a general increase in 
platelet reactivity, but overcompensation of negative feedback mechanisms that attenuate the 
platelet response to various thrombogenic substrates.  Moreover, reduced platelet count in 
Csk KO mice was not due to increased platelet clearance, but rather a reduction in platelet 
production, agreeing with a lack of activation and phagocytosis markers on platelets in these 
mice.  Although mean platelet count was rescued in DKO mice, the variability in count, 
platelet volume and the proportion of reticulated platelets in the circulation suggested a less 
robust system controlling platelet homeostasis in the absence of Csk and CD148. 
19 
 
Negative feedback mechanisms activated in the Csk KO and DKO mice, including 
downregulation of the (hemi-)ITAM-containing receptors GPVI-FcR γ-chain and CLEC-2, 
and upregulation of the ITIM-containing receptor G6b-B and tyrosine kinase Chk, likely 
represent cell-intrinsic adaptation of platelets to high SFK activity.  These findings are in 
agreement with the reduction of the ITAM-containing T cell receptor in Csk-deficient T 
cells,56 and increased phosphorylation of the ITIM-containing receptor Sirpα, the lipid 
phosphatase SHIP1 and Shp1 following inhibition of CskAS in immune cells.57  A plausible 
explanation for the downregulation of (hemi-)ITAM-containing receptors is that these 
receptors are direct substrates of CD148; similarly, the ITAM-containing T cell receptor 
subunit CD3 ζ-chain is suggested to be a substrate of the tyrosine phosphatase CD45.58,59  A 
clear difference was observed in the downregulation of GPVI-FcR γ-chain and CLEC-2, 
suggesting differential regulation of these receptors.  Whereas the GPVI-FcR γ-chain was 
severely reduced in both Csk KO and DKO platelets, CLEC-2 was markedly downregulated 
only in DKO platelets.  This may be explained by the different affinities of Syk to different 
phospho-(hemi-)ITAMs,60,61 and thus the ability of the SH2 domains of Syk to protect 
tyrosine residues within these motifs from dephosphorylation by CD148, as proposed for the 
related kinase ZAP-70.62-64  We hypothesize, that the higher affinity of the tandem SH2 
domains of Syk for the dual phospho-tyrosine residues of the FcR γ-chain ITAM in Csk KO 
platelets prevents CD148-mediated dephosphorylation.  Sustained phosphorylation would in 
turn lead to internalization and degradation of the GPVI-FcR γ-chain complex.  In contrast, 
due to the lower binding affinity of individual SH2 domains of Syk for single phospho-
tyrosine residues with the hemi-ITAM of CLEC-2, Syk is less capable of protecting CLEC-2 
from dephosphorylation by CD148.  As a consequence, less CLEC-2 is destined for 
degradation than FcR γ-chain in Csk KO platelets.  This is not however the case in DKO 
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platelets where no CD148 is present to dephosphorylate CLEC-2, hence it is markedly 
downregulated.  Further work is needed to validate this hypothesis. 
Analysis of tyrosine phosphorylation downstream of GPVI, CLEC-2 and αIIbβ3 
revealed that activation of Syk is not only dependent on SFK activity, but also on the 
presence of appropriate docking sites at the plasma membrane, providing evidence that 
increased SFK activity alone is insufficient to initiate downstream signaling.  A growing 
body of evidence has established G6b-B as a major inhibitor of (hemi-)ITAM-containing 
receptor signaling in platelets, acting primarily at the level of Syk.28,65  It is therefore likely 
that increased G6b-B expression, phosphorylation, and Shp1 and Shp2 association 
contributes to the attenuation of (hemi-)ITAM signaling in Csk KO and DKO platelets.  
Upregulation of Chk in the absence of Csk likely also contributes to the attenuation of SFK-
mediated signaling in these platelets, albeit less efficiently than it’s structurally related 
counterpart Csk.  Although, Chk was previously reported in platelets,66 it was not detected in 
either human or mouse platelets by mass spectrometry,3,4 in agreement with our findings from 
WT platelets.  Thus, the combination of reduced (hemi-)ITAM-containing receptor expression 
combined with increased ITIM-containing receptor and Chk expression result in a reduction 
in platelet reactivity to specific substrates.  This is better tolerated than pre-activated platelets 
that can trigger disseminated intravascular coagulation and death. 
To circumvent masking effects of negative feedback mechanisms in Csk KO or DKO 
mice, we utilized CskAS mice.  Inhibition of CskAS in platelets from these mice, resulted in 
significantly reduced phosphorylation of the C-terminal inhibitory tyrosine residues of SFKs, 
and increased SFK and Syk activity, similar to that reported in immune cells.39,57,67  However, 
inhibition of CskAS in platelets failed to have an effect on platelet aggregation.  This can be 
partially explained by increased formation of the G6b-B-Shp1-Shp2 complex, counter-acting 
the effect of increased SFK activity on Syk activation.25,28  Our findings also suggest that Csk 
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plays little role in attenuating GPVI and CLEC-2 signaling once initiated, mainly providing a 
break prior to ligand engagement and receptor clustering to prevent unwanted signaling by 
the receptors.  This was not however the case for αIIbβ3-mediated platelet spreading on 
fibrinogen, which was enhanced either in the absence of Csk or following inhibition of CskAS, 
suggesting Csk differentially regulates integrin and ITAM-containing receptor signaling.  
Previous work from our group suggests that G6b-B facilitates rather than inhibits integrin-
mediated responses in platelets and MKs,28 thus upregulation of the G6b-B-Shp1-Shp2 
complex is predicted to enhance rather than attenuate platelet spreading, as observed. 
In addition to filling a major gap in our knowledge of how SFKs are regulated in the 
MK lineage, findings from this study are also clinically relevant, demonstrating for the first 
time that either increased or decreased platelet SFK activity can lead to reduced thrombus 
formation and bleeding.  Our study highlights, that loss of an inhibitor of platelet activation, 
such as Csk, can lead to paradoxical bleeding due to the robust negative feedback 
mechanisms that get activated.  This may provide important mechanistic insights into the 
phenomenon of early platelet dysfunction observed in severe trauma patients displaying 
‘exhausted’ platelets,68 showing reduced thrombus formation on collagen.69  Our findings that 
platelets in the circulation can undergo cell-intrinsic changes, leading to downregulation of 
activation pathways and upregulation of inhibitory mechanisms may contribute to platelet 
dysfunction in trauma patients.  Moreover, certain tyrosine kinase inhibitors used to treat 
cancer patients inhibit SFKs or Csk and are accompanied with bleeding side-effects.  
Accordingly, the increased bleeding risk associated with use of the Bcr-Abl inhibitor 
Dasatinib is ascribed to its off-target effects on platelet SFKs.70,71  Similarly, bleeding-side 
effects of the Btk inhibitor Ibrutinib may be partially explained by its potent off-target effect 
on Csk.72,73  Based on our findings, CD148 is an attractive anti-thrombotic drug target, 
inhibition of which should attenuate, but not completely block any of the main platelet 
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activation pathways and have minimal bleeding side-effects.  Tyrosine phosphatases are 
increasingly considered to be druggable,74 supported by the recent development of the highly 
specific Shp2 inhibitor SHP099,75 thus targeting CD148 is not inconceivable. 
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Table 1.  Summary of Csk KO, CD148 KO and DKO mouse phenotypes. 
 
Phenotype 
 Genotype  
Csk 
KO 
CD148 
KO DKO 
Bleeding ↑ — ↑↑ 
Thrombosis 
   
In vivo 
   
     Laser injury ↓ ↓ ↓↓ 
     FeCl3 injury ↓↓ ↓ ↓ 
Ex vivo 
   
     T-TAS – collagen ↓ ↓ ↓↓ 
                 – collagen, tissue factor — — — 
     Flow chamber – collagen ↓ ↓ ↓↓ 
                             – vWF-BP, laminin, rhodocytin ↓ ↓ ↓ 
Platelet count ↓ — — 
Platelet receptors 
   
      Expression 
   
            GPVI-FcRγ-chain ↓↓ ↓ ↓↓↓ 
            CLEC-2 ↓ — ↓↓ 
            G6b-B ↑↑ — ↑↑ 
      Phosphorylation 
   
            G6b-B ↑↑ — ↑↑↑ 
SFK activity ↑ ↓ ↑↑ 
 
↑ upregulated, ↓ downregulated, — normal 
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Figure Legends 
Figure 1.  Aberrant platelet production and platelet receptor expressions in Csk KO 
mice.   
(A) Platelet lysates were blotted for the indicated proteins.  (B) Platelet counts.  (C) 
Percentage of reticulated platelets determined by thiazole orange+αIIb+ cells in blood.  See 
also Figure S2A.  (D) i) Median fluorescence intensity (MFI) measured in αIIb+ cells alone or 
αIIb+ cells co-stained for the indicated proteins in blood, n = 5-6 mice/genotype.  See also 
Figure S3.  ii) Platelet lysates were blotted for the indicated proteins.  (E) i) Platelet counts of 
pre-/post-injection of anti-GPIbα antibody (1.5 μg/g of body weight).  ii) The rate of platelet 
recovery determined by a proportionate slope from linear trend lines between day 3 to 7 from 
(i), n = 7-8 mice/genotype. See also Figures S4-6. 
Asterisks refer to significant difference compared to WT.  *P < 0.05, ***P < 0.001, one-way 
ANOVA with Tukey’s test (B-D), or one-way ANOVA with Dunnett’s test; vs WT (E), mean 
± SEM. 
 
Figure 2.  Increased bleeding and defective thrombus formation in Csk KO and DKO 
mice. 
(A) Hemostatic response was measured in tail bleeding assays by an excision of a 5-mm 
portion of the tail tip followed by the determination of lost blood/body weight (normalized 
blood loss), n = 11-57 mice/genotype.  Tail bleeding assays were conducted in a double-
blinded manner.  (B) Laser injury-induced thrombus formation in vivo.  Composite 
brightfield and fluorescence images of i) platelet accumulation (green) or ii) fibrin generation 
(red) in cremaster muscle arterioles monitored by DyLight488-labaled anti-GPIbβ antibody 
(0.1 μg/g of body weight) or Alexa-Fluor 647-labeled anti-fibrin antibody (0.2 μg/g of body 
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weight) signal, respectively by confocal intravital microscopy (scale bar: 10 μm).  Each curve 
represents the median integrated fluorescence intensity of iii) platelets or iv) fibrin in relative 
fluorescence units (RFU), n = 25-37, in 5 mice/genotype.  See also Videos 1 and 2.  (C) 
Ferric chloride injury-induced thrombus formation in vivo.  Filter paper soaked in 10% ferric 
chloride was applied to carotid artery for 3 minutes.  i) Representative fluorescence images of 
platelet accumulation (green) monitored by DyLight488-labaled anti-GPIbβ antibody (0.1 
μg/g of body weight) by confocal intravital microscopy (scale bar: 200 μm).  ii) Each curve 
represents the median integrated thrombus fluorescence intensity in RFU.  iii) Area under the 
curve (AUC) was measured, n = 8-11 mice per genotype.  See also Video 3.  
*P < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA with Tukey’s test; mean ± SEM 
 
Figure 3.  Aberrant platelet functions in Csk KO, CD148 KO and DKO mice. 
(A) i) 25 μg/ml hirudin-treated blood was perfused with collagen-coated chip at 1000 s-1 for 
10 minutes.  Individual time-dependent flow pressure curves and total thrombogenicity (Area 
under the curve: AUC) were measured by the total thrombus-formation analysis system (T-
TAS).  ii) Blood treated with 3.2% sodium citrate, 12 mM CaCl2 and 50 μg/ml corn trypsin 
inhibitor was perfused on collagen plus tissue thromboplastin (tissue factor)-coated chip at 
240 s-1 for 30 minutes.  Individual time-dependent flow pressure curves, time to onset (T10), 
time to occlusion (T80), rate of thrombus growth (T10-80) and AUC were measured by T-
TAS, n = 4-9 per genotype.  (B) Blood treated with 5 Unit/ml Heparin, 40 μM PPACK and 
50 Unit/ml Fragmin was perfused over microspots with indicated coatings; 100 μg/ml 
collagen I, 12.5 μg/ml vWF-binding peptide (vWF-BP), 50 μg/ml laminin, 250 μg/ml 
rhodocytin for 3.5 minutes at 1,000 s-1. i) Representative bright field images with indicated 
surfaces.  ii) Platelet deposition (% surface area coverage; SAC).  iii) Multilayered thrombus 
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(% SAC) on collagen I surface.  iv) Representative fluorescence images of P-selectin, 
integrin αIIbβ3 activation (JON/A) and PS exposure (Annexin V) from collagen surface and 
v) % SAC of fluorescence images.  vi) Heatmap of outcome parameters expressed as effect 
sizes per genotype;76 P1, platelet deposition, P2, multilayered thrombus, P3, P-selectin, P4, 
JON/A, and P5, PS exposure from indicated surfaces.  Scale bar: 10 μm.  Experiments and 
analysis were performed in a double-blinded manner.  % SAC was analyzed using Fiji 
programme, n = 15 images from 5 mice per genotype.  (C) Representative platelet 
aggregation and ATP secretion traces in response to the indicated agonists in i-vi) washed 
platelets or vii) ADP-sensitive washed platelets.  See also Figure S7.  n = 4-8 
mice/condition/genotype.  (D) i) Representative differential interference contrast (DIC) 
microscopy images of resting (basal) and thrombin-stimulated (0.1 Unit/ml, 5 minutes) 
platelets spread on fibrinogen-coated cover-slips (100 μg/ml, 45 minutes, 37°C, scale bar: 5 
μm).  ii) Mean surface area of individual platelets quantified by ImageJ software, n = 256 
platelets/condition/genotype.  (E) Fibrin clot retraction was assessed 2 hours after the 
addition of 1 Unit/ml thrombin and 2 mM CaCl2 to platelet-rich plasma.  Clot volumes were 
expressed as a percentage of the initial volume of platelet-rich plasma, n = 8 per genotype. 
*P < 0.05, **P < 0.01, ***P < 0.001, two-way (Bii, Bv, and D) or one-way (A, Biii, and E) 
ANOVA with Tukey’s test, mean ± SEM. 
 
Figure 4.  Csk and CD148 reciprocally regulate platelet SFKs. 
(A) i) Representative electropherograms of capillary-based immunoassays on platelet lysates 
with the indicated antibodies and the quantification of peak areas, n = 6 mice/genotype.  ii) 
Representative data from i) displayed as blots.  See also Figure S8.  (B) Model of SFK 
regulation in platelets.  In WT platelets, SFKs are constrained in an inactive conformation by 
Csk, which phosphorylates the C-terminal inhibitory tyrosine residue.  SFKs can be activated 
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by dephosphorylation of the inhibitory residue by CD148.  SFKs trans-auto-phosphorylate 
each other at the activation-loop tyrosine residue and become fully active.  CD148 can also 
dephosphorylate the activation-loop tyrosine leading to a decrease in SFK activity.  In Csk 
KO platelets, CD148 dominates resulting in the loss of inhibitory phosphorylation and a net 
increase in SFK activity.  In CD148 KO platelets, Csk dominates resulting in increased 
inhibitory phosphorylation, and markedly decreased activation-loop phosphorylation.  In 
DKO platelets, the absence of both Csk and CD148 leads to a dramatic increase in SFK 
activity.  The differential phosphorylation of SFKs in Csk KO and DKO platelets supports the 
hypothesis of CD148 dephosphorylating both the activation-loop and the C-terminal 
inhibitory tyrosine residues.  (C) Platelet lysates were blotted for the indicated proteins. 
*P < 0.05, **P < 0.01, ***P < 0.001, repeated measures (RM) one-way ANOVA with 
Tukey’s test, mean ± SEM. 
 
Figure 5.  Csk and CD148 are critical for platelet activation signals.   
(A) i) Lysates of basal and collagen-stimulated (30 μg/ml, 90 seconds) platelets were blotted 
for p-Tyr and tubulin.  ii-iii) Same lysates were analyzed by capillary-based immunoassays 
with the indicated antibodies. ii) Representative data displayed as blots.  iii) Quantification of 
peak areas from Figure S9A , n = 3-4 mice/genotype.  See also Figure S9A.  (B) i-iii) Lysates 
of basal and CLEC-2 antibody-stimulated (10 μg/ml, 5 minutes) platelets were analyzed as 
described in (A), n = 3-4 mice/genotype.  See also Figure S9B.  (C) i-iii) Lysates of non-
adherent (NA) and adherent (Ad) platelets from fibrinogen-coated plates  (100 μg/ml, 45 
minutes, 37°C) were analyzed as described in (A).  See also Figure S9C.  iv) Same lysates 
were blotted for Syk p-Tyr525/6, n = 3-4 mice/genotype.  Differences in basal SFK p-Tyr418 
between WT and DKO platelets in suspension (A-B) compared with non-adhered platelets (C), 
are due to differences in sample preparation, as demonstrated by a significant increase in Src 
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p-Tyr418 levels in non-adhered platelets incubated on fibrinogen-coated surface (Figure 
S9D).   
(D) i) Increased G6b-B phosphorylation and assembly of the G6b-B-Shp1-Shp2 complex in 
Csk KO and DKO platelets.  Lysates of basal and collagen-stimulated (30 μg/ml, 90 seconds) 
platelets were immunoprecipitated with anti-G6b-B antibody and blotted for p-Tyr, G6b-B, 
Shp1 and Shp2.  ii) The role of SFKs in activating and inhibitory pathways.  Once a threshold 
level of SFK activity is reached, ITAM, integrin and ITIM signaling are triggered.  The 
kinetics and order of activation depend upon the agonist and level of SFK activity. 
*P < 0.05, **P < 0.01, ***P < 0.001, RM two-way ANOVA with Tukey’s test, mean ± SEM.   
 
Figure 6.  Csk regulates ITAM-, ITIM- and integrin-dependent signaling in CskAS 
platelets. 
(A-E) Platelets from CskAS mice were pre-treated with either DMSO or 3-IB-PP1 (10 μM, 10 
minutes).  (A) i-iv) Representative aggregation and ATP secretion traces of platelets from 
CskAS mice in response to the indicated agonists, n = 3-4 mice/condition/genotype.  (B) i) 
Representative DIC microscopy images of resting (basal) and thrombin-stimulated (0.1 
Unit/ml, 5 minutes) platelets spread on fibrinogen-coated cover-slips (100 μg/ml, 45 minutes, 
37°C, scale bar: 5 μm).  ii) Mean surface area of individual platelets quantified by ImageJ 
software, n = 256 platelets/condition/genotype.  (C and D) Lysates of platelets incubated with 
or without CRP (30 μg/ml, C) or CLEC-2 antibody (10 μg/ml, D) for indicated times were i) 
blotted for p-Tyr and actin, or ii-iii) analyzed by capillary-based immunoassays as described 
in Figure 5A, n = 3-4 mice/genotype.  See also Figure S10A-B.  (E) Increased G6b-B 
phosphorylation and assembly of the G6b-B-Shp1-Shp2 complex in collagen-stimulated 
CskAS platelets treated with 3-IB-PP1.  Lysates of basal and collagen-stimulated (30 μg/ml, 
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90 seconds) platelets were immunoprecipitated with anti-G6b-B antibody and blotted for p-
Tyr, G6b-B, Shp1 and Shp2. 
*P < 0.05, **P < 0.01, ***P < 0.001, ordinary (B) or RM (C and D) two-way ANOVA with 
Sidak’s test, mean ± SEM. 
 
Figure 7.  Regulation of platelet SFKs by the kinase Csk, and the phosphatase CD148. 
(A) Csk and CD148 are the main regulators of SFK activity in platelets and impact on 
different platelet signaling pathways.  Csk inhibits SFK activity, whereas CD148 activates 
SFKs but it can also inhibit SFK activity under as yet undefined conditions.  In turn, SFKs 
regulate ITAM, integrin, ITIM and P2Y12 receptor signaling pathways.  See also Figures 4B 
and 5Dii.  (B) Post-activated platelets.  Platelets possess remarkable positive-feedback 
pathways (e.g. ADP, TXA2), which further enhance platelet activation.  Platelet activation is 
followed by receptor proteolysis or internalization, de novo protein synthesis and 
downregulation of tyrosine phosphorylation pathways by ITIM-containing receptors and 
phosphatases.  Csk KO and DKO platelets have increased SFK activity which results in 
reduced expression of the platelet activating receptors GPVI and CLEC-2, increased 
expression of the ITIM-containing receptor G6b-B and increased ITIM signaling suggesting 
that these platelets exist in a ‘post-activated’ state. 
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Supplemental Materials and Methods 
Antibodies 
The following antibodies were used in this study:  anti-GPIb (Xia.G5), anti-Integrin 2 
(Sam.G4), anti-GPVI (JAQ1), anti-P-selectin (Wug.E9), anti-high affinity conformation of 
CD41/CD61 (JON/A), rat IgG, anti-GPIbfor platelet depletion (R300), and anti-GPIbfor 
in vivo mouse platelet labelling (X488) from emfret ANALYTICS;  anti-CD41 (MWReg30) 
and Streptavidin from BD Pharmingen; anti-ADAM10 ectodomain (139712) from R&D 
system; anti-CLEC-2 (17D9) and rat IgG2b from AbD Serotec; anti-Csk (C-20), anti-Ctk 
(Chk, C-20), anti-SH-PTP1 (C-19), anti-SH-PTP2 and anti-rat IgG-HRP from Santa Cruz;  
anti-Src (pY418), anti-Src (pY529), annexin V Alexa Fluor 647 conjugate, and Alexa Fluor 
488 and Alexa Fluor 647 antibody labelling kit from Invitrogen Life Technologies; anti-Lyn 
(pY507), anti-Syk (pY525/526), anti-Syk (D1I5Q) and anti-Src from Cell Signaling; anti-Fyn 
(pY530) and anti-syrian hamster IgG-HRP from Abcam; anti-PTP-1B, anti-Fc epsilon RI 
gamma subunit, and anti-phophotyrosine (4G10) from Millipore; anti--tubulin (DM1A) 
from Sigma; anti-mouse and anti-rabbit ECL HRP conjugates from GE Healthcare; anti-
CD148 (8A-1) antibody has been previously described;
1
 anti-G6b-B (68-3), (N24) and anti-
GPVI antibodies have been previously described.
2
  Anti-fibrin antibody (clone 59D8), a 
generous gift from Dr. Timothy J. Stalker (University of Pennsylvania), has been previously 
described,
3
 and labeled using Alexa Fluor monoclonal antibody labeling kits from Invitrogen. 
 
Platelet clearance 
Mice were injected intravenously with 150 l of biotin-N-hydroxysuccinamide (4 mg/ml in 
saline, Sigma-Aldrich).  The percentage of biotin
+IIb+ platelets in blood was measured in 
IIb+ cells co-stained with streptavidin daily post-injection and the percentage of labelled 
platelets remaining in the circulation was determined by flow cytometry.  The rate of platelet 
clearance was determined by a proportionate slope from linear trend lines between days 1 to 
3. 
 
Immunohistochemistry 
Spleens and femurs were fixed in buffered formalin and embedded in paraffin.  Sections (5 
m) were hematoxylin and eosin (H&E) or reticulin stained. Images were obtained by Slide 
Scanner Axio Scan.Z1 brightfield microscope and Axio Zen software (Zeiss).  Analysis of 
MK counts in spleen and femur per view was performed in a double blinded manner. 
 
Isolation of bone marrow cells and in vitro differentiation of megakaryocytes 
Bone marrow was flushed using DMEM media supplemented with 10 % FBS, glutamine and 
penicillin/streptomycin using a 25 gauge needle from femora and tibiae of mice and the cells 
were spun down.  Bone marrow cells were resuspended in ACK buffer (0.15 M NH4Cl, 1 
mM KHCO3, 0.1 mM Na2EDTA,  pH 7.3) in order to lyse erythrocytes and filtered by a 70 
m nylon mesh and subsequently resuspended in P2 buffer (PBS, 5 % FBS, 1 % BSA)  for 
flow cytometry assay.  Surface protein expression was measured in bone marrow cells with 
indicated FITC- or PE-conjugated antibodies by flow cytometry (BD FACSCalibur).  Median 
fluorescence intensity (MFI) were measured in IIb+ gated population, and analysed at least 
50,000 events for bone marrow cells.  To culture megakaryocytes (MKs) for biochemical 
assay, cells expressing one or more of the lineage specific markers on their surface 
(CD16/CD32
+
, Gr1
+
, B220
+
, CD11b
+
) were depleted using immunomagnetic beads (sheep 
anti-rat IgG Dynabeads).  The remaining population was cultured in 2.6% serum-
supplemented Stempro medium with 2 mM L-glutamine, penicillin/streptomycin and 20 
ng/ml murine SCF at 37°C and 5% CO2 for 2 days.  Cells were then cultured for a further 4 
days in the presence of 20 ng/ml SCF and 50 ng/ml Tpo.  After 4 days of culture in the 
presence of Tpo, mature MKs were enriched using a 1.5%/3% BSA gradient under gravity (1 
×g) for 45 minutes at room temperature.  MKs were starved for 3 hrs at 37°C in serum-free 
media to obtain whole-cell lysates as previously described.
4
 
 
Total thrombus-formation analysis system (T-TAS) 
Blood treated with 25 g/ml hirudin was perfused with collagen-coated chip with shear rate 
1000 s
-1
 for 10 minutes.  Blood treated with 3.2% sodium citrate, 12 mM CaCl2 and 50 g/ml 
corn trypsin inhibitor was perfused with collagen plus tissue thromboplastin (tissue factor)-
coated chip with shear rate 240 s
-1
 for 30 minutes.  Individual time-dependent flow pressure 
curves, time to onset (T10), time to occlusion (T80), rate of thrombus growth (T10-80) and 
total thrombogenicity (Area under the curve: AUC) were measured by the total thrombus-
formation analysis system (T-TAS, Fujimori Kogyo, Japan). 
 
Whole-blood thrombus formation and platelet adhesion under flow 
Mouse blood anticoagulated with 5 Unit/ml heparin, 40 M PPACK and 50 Unit/ml fragmin 
was perfused for 3.5 minutes at 1,000 s
-1
 over glass coverslips coated with microspots of 
agonists; 100 g/ml collagen type I, 12.5 g/ml vWF-binding peptide (VWF-BP), 50 g/ml 
laminin, and 250 g/ml rhodocytin.  Brigtfield and three-color fluorescence images were 
captured with an EVOS microscope (60x oil) (Life Technologies) and analysed using Fiji as 
previously described.
5
 
 
Platelet aggregation and secretion 
Aggregation and adenosine triphosphate (ATP) secretion were performed in a lumi-
aggregometer (Chrono-Log, Havertown, PA) with continuous stirring at 1200 rpm at 37 C 
for the times shown, and monitored by measuring changes in light transmission.  
Static adhesion spreading assay 
Washed platelets were pre-incubated with or without thrombin (0.1 Unit/ml, 5 minutes) 
placed on fibrinogen-coated cover-slips (100 g/ml, 45 minutes, 37C) and imaged (63x oil 
immersion lens), as previously described.
6
  
 
Clot retraction 
Platelet-rich plasma (PRP) was prepared from blood treated with 4% (w/v) sodium citrate by 
centrifugation at 200 g for 8 minutes at room temperature in the presence of prostacyclin (0.1 
g/ml) and adjusted to a concentration of 2 x 108 platelets/ml by platelet-poor plasma (PPP) 
which was prepared by centrifugation 1000 g for 10 minutes at room temperature.  Fibrin clot 
retraction was performed by incubating 200 l of PRP (4 x 107 platelets) in the presence of 1 
Unit/ml thrombin and 2 mM CaCl2 for 2 hours at room temperature in an aggregometer 
cuvette.  A paper clip was added to facilitate clot removal at the termination of the 
experiment.  The volume of residual clot-free plasma was determined, and clot volume was 
taken as 200 l minus this value. Clot volume was expressed as a percentage of the original 
200 l plasma volume.   
 
Platelet stimulation for biochemical analysis 
For biochemical analysis of GPVI and CLEC-2 signaling pathways, platelets were pre-
incubated with lotrafiban (10 M), apyrase (2 Unit/ml) and indomethacin (10 M) for 10 
minutes.  Afterwards, platelets were stimulated under stirring conditions (1200 rpm, 37C) 
with collagen, CRP or CLEC-2 antibody for indicated times. 
For biochemical analysis of the integrin IIb3 outside-in signaling pathway, 
platelets were pre-incubated with apyrase (2 Unit/ml) and indomethacin (10 M) for 10 
minutes, and then placed on fibrinogen-coated plates (100 g/ml) for 45 minutes at 37C.  
Non-adherent platelets were used as controls.  
After stimulating GPVI, CLEC-2 or IIb3 outside-in signaling pathways for the 
specified times, platelets were lysed with an equal volume of ice cold 2 x lysis buffer (2% 
Nonidet P-40, 300 mM NaCl, 20 mM Tris, 10 mM EDTA, 2 mM Na3VO4, 200 g/ml 4-(2-
aminoethyl) benzenesulfonyl fluoride hydrochloride, 10 g/ml leupeptin, 10 g/ml aprotinin, 
and 1 g/ml pepstasin A, pH 7.4).  In case of fibrinogen-adherent platelets, ice cold 1 x lysis 
buffer was used to lyse cells for 15 minutes on ice, which was followed by scraping platelets 
off the plates.  Insoluble cell debris was removed by centrifugation for 5 minutes at 13,000 x 
g, 4C, and whole cell lysates (WCLs) were precleared using protein G- or A-Sepharose 
(Sigma-Aldrich) for 30 minutes.  G6b-B was immunoprecipitated from collagen-stimulated 
WCLs with anti-G6b-B antibody as previously described.
2
 
 
Immunoblotting 
WCLs were either boiled in SDS-loading buffer, and analyzed by SDS-PAGE and traditional 
Western blotting or analyzed on an automated capillary-based immunoassay platform; Wes 
(ProteinSimple, San Diego, USA) for quantitative analysis.  WCLs to be analyzed on the Wes 
system were prepared according to manufacturer’s instructions and were not precleared.  
Protein concentrations were determined using the Bio-Rad RC DC protein assay.  Diluted 
samples and primary antibody were added to pre-filled microplates with Split Running Buffer 
(PS-MK14).  Before analyzing WCLs from transgenic mouse platelets, optimal lysate and 
antibody concentrations were determined on WT WCLs.  Briefly, for each antibody used, a 
lysate dilution experiment was performed to confirm the optimal dynamic range of the 
protein on Wes. This was followed by an antibody optimization experiment to compare a 
range of dilutions and select an antibody concentration near to saturation level to allow a 
quantitative comparison of signals between samples.  In each run, twenty-four samples were 
analyzed in parallel as triplicates of eight samples from the same experiment for either Src, 
Src p-Tyr418 and Lyn p-Tyr507 on one microplate (plate A) or Src p-Tyr529, Fyn p-Tyr530 
and Syk p-Tyr525/6 on another microplate (plate B).  Compass Software (ProteinSimple, San 
Diego, USA) was used to operate Wes and analyze results.  Separation time was set to 31 
minutes, stacking loading time to 21 seconds and sample loading time to 9 seconds for both 
microplates.  Primary antibody incubation time was 60 minutes for plate A and 30 minutes 
for plate B, and exposure times were 5;  15; 30; 60; 120; 240 and 480 seconds for plate A and 
2; 5; 10; 20; 40; 80 and 160 seconds for plate B.  The defined antibody and lysate 
concentrations were as follows: anti-Src antibody (1:50 dilution), anti-Src p-Tyr529 antibody 
(1:100 dilution) and anti-Fyn p-Tyr530 antibody (1:50 dilution) were used for 0.025 mg/ml 
platelet and 0.1 mg/ml MK lysate concentration; anti-Src p-Tyr418 antibody (1:10 dilution) 
was used for 0.05 mg/ml platelet and 0.1 mg/ml MK lysate concentration; anti-Lyn p-Tyr507 
antibody (1:10 dilution) was used for 0.2 mg/ml platelet and 0.4 mg/ml MK lysate 
concentration; anti-Syk p-Tyr525/6 antibody (1:50 dilution) was used for 0.1 mg/ml platelet 
lysate concentration.  The only exception from the above described concentrations were 
CLEC-2-stimulated samples in Figure 6 B in which case Syk p-Tyr525/6 antibody (1:50 
dilution) was used in combination with 0.05 mg/ml platelet lysate concentrations. 
 
Statistical analysis 
Quantification of data is indicated in the figures, figure legends and methods sections. 
Statistical parameters including the exact value of n, the definition of center, dispersion and 
precision measures (mean ± SEM) and statistical significance are reported in the figures and 
figure legends.  Sample number (n) indicates the number of independent biological replicates 
in each experiment in most figures, the number of images of H&E-stained spleen and femur 
sections in Figure S6A-B, the number of individual platelets in Figure 3Dii and 6Bii, and the 
number of injury induced in Figure 2Ciii.  For multiple group comparisons, one-way or two-
way ANOVA followed by post-hoc tests was used to determine statistical significance.  Data 
from the Wes system were analyzed using repeated measures (RM) one-way ANOVA 
(Figure 4Ai and Figure S8A) or RM two-way ANOVA (Figures 5A-C and 6C-D) to control 
for variability in different experiments and Wes runs or by t-test (Figure S9D).  RM two-way 
ANOVA was also used to analyze data from traditional Western blots (Figure 5Civ).  
Ordinary one- or two-way ANOVA was used to analyze the rest of the figures.  P values < 
0.05 were considered significant.  In figures, asterisks denote statistical significance 
compared to WT (Figure 1-5) or DMSO-incubated control samples (Figure 6).  Statistical 
analysis was performed in GraphPad Prism 6 (GraphPad Software, La Jolla, CA), except 
statistical analysis of platelet clearance and recovery, which were performed in Excel. 
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 Supplemental table 
Parameter 
WT 
(n = 42-67) 
Csk KO 
(n = 26) 
PLT (103/mL) 825.1 ±83.1 289.9 ±125.15*** 
MPV (fL) 5.65 ±0.38 7.14 ±1.36*** 
RBC (106/mL) 9.68 ± 1.07 9.03 ± 0.67 
HCT (%) 28.07 ± 3.94  27.29 ± 2.07 
WBC (103/mL) 7.39 ± 2.86  8.40 ± 3.80 
LYM (103/mL) 6.56 ± 2.53 6.91 ± 3.36 
MON (103/mL) 0.28 ± 0.24 0.67 ± 0.40*** 
NEU (103/mL) 0.53 ± 0.38  0.74 ± 0.33 
EOS (103/mL) 0.008 ± 0.03  0.01 ± 0.03 
BAS (103/mL) 0.03 ± 0.06 0.07 ± 0.07 
Table S1.  Hematological analysis of Csk KO, CD148 KO and DKO mice. 
CD148 KO 
(n = 12 -18) 
772.0 ±96.2 
5.78 ±0.46 
9.63 ± 1.40 
 26.31 ± 5.02 
 8.37 ± 4.32 
7.02 ± 3.78 
0.48 ± 0.49 
 0.76 ± 0.62 
 0.02 ± 0.05 
0.03 ± 0.04 
DKO 
(n = 24-27) 
809.3 ±197.5 
6.60 ±0.53*** 
9.37 ± 0.86 
 27.36 ± 2.64 
 11.61 ± 4.98*** 
8.84 ± 4.09* 
1.58 ± 0.70*** 
 1.05 ± 0.44*** 
 0.04 ± 0.07* 
0.10 ± 0.19* 
PLT, platelets; MPV, mean platelet volume; RBC, red blood cells;  HCT, haematocrit, WBC, white blood 
cells; LYM, lymphocytes; MON, monocytes; NEU, neutrophils; EOS, eosinophils; BAS, basophils 
Mean ± standard deviation, *P < 0.05, ***P < 0.001, one-way ANOVA with Tukey’s test  
Figure S1.  Expression levels of SFKs in platelets. 
Number of copies of SFKs’ expression in (A) human platelets3 and (B) mouse platelets4 are displayed as 
percentage values in a pie chart.  
Human Mouse A B 
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Figure S2.  Increased immature platelet fraction but normal platelet P-selectin expression in 
Csk KO mice.  (A) Representative image of reticulated platelet population in flow cytometry.  
Reticulated platelets in whole blood were measured in thiazole orange/aIIb double-positive cells 
detected by flow cytometry.  aIIb positive platelets in whole blood are gated and the percentage of 
reticulated platelets was determined in region 1 (R1; in red) in dot plot diagram forward scatter 
(FSC) vs. RNA dye (Thiazole Orange).  See also Figure 1C.  (B) Percentage of P-selectin+aIIb+ 
platelets in blood. *P < 0.05, one-way ANOVA with Tukey’s test, mean ± SEM.  
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Figure S3.  Normal platelet and aIIb+ bone marrow cell 
surface receptor expression in Csk KO, CD148 KO and 
DKO mice. (A) Median fluorescence intensity (MFI) measured 
in aIIb+ cells co-stained for the indicated proteins in blood by 
flow cytometry. See also Figure 1Di.  (B) Median fluorescence 
intensity (MFI) measured in aIIb+ cells alone or aIIb+ cells co-
stained for the indicated proteins in bone marrow by flow 
cytometry.  Data are represented as scatter plots with mean ± 
SEM from 3-16 biological replicates, one-way ANOVA with 
Tukey’s test. 
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Figure S4.  Normal platelet clearance in Csk KO mice. (A) Percentage of biotin+aIIb+ platelets in blood 
of post-injection of 150 µl biotin-N-hydroxysuccinamide.  (B) The rate of platelet clearance determined by 
a proportionate slope from linear trend lines between day 1 to 3 from (A), n = 6 mice/time point/genotype. 
One-way ANOVA with Dunnett’s test; vs WT, mean ± SEM.  
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Figure S5.  Splenomegaly in Csk KO and DKO mice.  (A) Gross morphology of 
representative spleens (scale bar: 5 mm) and (B) spleen/body weight ratio.  
***P < 0.001, one-way ANOVA with Tukey’s test  
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Figure S6.  Extramedullary hematopoiesis and 
myelofibrosis in Csk KO and DKO mice. (A-B) 
Representative Haematoxylin and eosin (H&E) 
and reticulin staining in (A) spleen and (B) femur 
(scale bar: 50 mm).  Analysis of megakaryocyte 
(MK) count per view was performed in a double-
blinded manner., n = 75-100 images from 5 
mice/genotype.  (C) Percentage of P-selectin+aIIb+ 
bone marrow (BM) cells.  **P < 0.05, ***P < 0.001, 
one-way ANOVA with Tukey’s test , mean ± SEM. 
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Figure S7.  Increased ADP response in DKO mice.  ADP-sensitive washed 
platelets were prepared in the presence of ADP scavenger apyrase and used at 
2  108/ml.  % of  platelet aggregation in response to indicated dose of ADP were 
analyzed.  See also Figure 3Cvii.  Data are represented as scatter plots with 
mean ± SEM from 4-8 biological replicates, one-way ANOVA with Tukey’s test. 
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 Supplemental figures Figure S7 
Figure S8.  Increased megakaryocyte SFK activity in Csk KO mice.  SFK activation loop and 
inhibitory tyrosine phosphorylation levels in bone marrow-derived megakaryocytes.  (A) Representative 
electropherograms of capillary-based immunoassays on ex vivo differentiated megakaryocyte lysates 
with the indicated antibodies and the quantification of peak areas, n=4 mice/genotype.  (B) 
Representative data from i) displayed as blots.  *P < 0.05, **P < 0.01, RM one-way ANOVA with 
Tukey’s test, mean ± SEM.  
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 Supplemental figures Figure S8 
A Collagen stimulation 
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B CLEC-2 antibody stimulation 
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 Supplemental figures Figure S9 
C Fibrinogen stimulation 
Figure S9.  SFK activation loop and inhibitory tyrosine phosphorylation 
levels in activated platelets in Csk KO, CD148 KO and DKO mice.  (A-C) 
Representative electropherograms of capillary-based immunoassays on platelet 
lysates with the indicated antibodies.  Platelets were stimulated with A) collagen 
(30 mg/ml, 90 seconds), B) CLEC-2 antibody (10 mg/ml, 5 minutes)  or C) were 
allowed to spread on fibrinogen-coated plates  (100 mg/ml, 45 minutes, 37C). 
(D) Src p-Tyr418 / GAPDH peak area ratio of resting and non-adherent WT 
platelets from fibrinogen-coated plates  (100 mg/ml, 45 minutes, 37C). Lysates 
were analyzed by capillary-based immunoassays for Src p-Tyr418 and GAPDH, 
n = 7 mice.  **P < 0.01, paired, two-tailed t-test, mean ± SEM.  
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Figure S10.  SFK activation loop and inhibitory tyrosine phosphorylation levels in activated platelets in 
CskAS mice.  (A-B) Representative electropherograms of capillary-based immunoassays on platelet lysates with 
the indicated antibodies.  Platelets from CskAS mice were pre-treated with either DMSO (D) or 10 mM 3-IB-PP1 
(I) for 10 minutes and  stimulated with A) CRP (30 mg/ml) or B) CLEC-2 antibody (10 mg/ml) for indicated times. 
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Videos 
Video 1.  Representative laser-induced thrombus formation  
in WT, Csk KO, CD148 KO and DKO mice.  
 
Video 2. Representative laser-induced fibrin formation in WT, Csk KO, CD148 KO 
and DKO mice.  
 
Video 3. Representative ferric chloride-induced thrombus formation in WT, Csk 
KO, CD148 KO and DKO mice.  
 
